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ABSTRACT
Exosomes are small, extracellular mem-
brane-bound particles that mediate intercellular
transport of a cytosolic cargo. Exosomal transfer
of micro-RNA can modify gene expression in
targeted cells. Exosome-based endocrine/para-
crine signaling has been shown to be involved
in a wide range of physiological processes
including those associated with cardiovascular
injury and disease, but remains relatively poorly
understood. Exosomes offer great potential to
the clinical field, with applications in both
diagnostics and therapeutics. A stable, circulat-
ing form of micro-RNA exists in blood protected
from endogenous nucleases. This population of
micro-RNA, which includes both exosomal and
non-exosomal fractions, may be isolated from
blood and exploited as a novel disease bio-
marker with the potential to deliver increased
specificity and rapid diagnosis compared to
conventional biomarkers. Exosomes also offer a
natural drug-delivery vehicle, providing
immune evasion and specific targeting through
engineering of surface-displayed ligands. Much
of the cardioprotective and regenerative bene-
fits of stem-cell grafts are now thought to derive
from paracrine signaling rather than direct tis-
sue incorporation and therefore stem cell-der-
ived exosomes offer the potential for a
convenient cell-free therapeutic option, elimi-
nating many of the risks and variability associ-
ated with stem-cell therapy. In this review, we
consider the potential applications of this
emerging field to cardiovascular medicine, tak-
ing myocardial infarction as our primary
example.
Keywords: Acute myocardial infarction;
Biomarker; Cardiovascular disease; Circulating
micro-RNA; Drug delivery; Exosome; Micro
RNA; Nanoparticle; Stem cell therapy; Troponin
EXOSOMES REPRESENT A NEW
PARADIGM FOR ENDOCRINE/
PARACRINE SIGNALING
Exosomes are small membrane-bound particles
actively released by cells under both physio-
logical and stressed conditions. Exosomes carry
a cargo of RNA and soluble proteins and display
specific receptors on their surface that may
function in targeting to specific receiver cells.
RNA carried by exosomes includes both mRNA
and micro-RNA (miR) and these RNAs are able
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to modify gene expression within receiver cells
[1–3]. Exosomes have been shown to mediate a
number of paracrine signals within the cardio-
vascular system, for example, between the vas-
cular endothelium and smooth muscle [4],
between cardiac fibroblasts and cardiomyocytes
[5], and between vascular smooth muscle cells
[6]. Exosomes of cardiovascular origin are also
present in the pericardial fluid [3] and in blood
[7, 8], indicating their likely involvement in
endocrine signaling. Changes in circulating
exosomes are linked to diseased states [7–9],
suggesting their potential as a diagnostic bio-
marker. Exosomes can be isolated from the
conditioned media of cells in vitro and this,
together with the relative ease of engineering
both exosome cargo and surface displayed pro-
teins offers much potential for therapeutic drug
delivery.
Exosomes represent one of three broad classes
of extracellular vesicle. Membrane blebbing
from cells undergoing apoptosis generates
so-called apoptotic-bodies [10, 11] of a size
generally between 0.5 and 2 lm. Although
apoptotic bodies have been shown to mediate
cell signaling under certain circumstances
[12, 13], they are normally regarded as a passive
by-product of cellular breakdown and thus of
limited interest. Ectosomes (also known as
shedding microvesicles) are produced by out-
ward-budding (ectocytosis) of the plasma mem-
brane, and are generally larger than exosomes
[14, 15]. In contrast, exosomes are actively pro-
duced in the endosomal pathway. Exosome
biogenesis involves endocytosis from the plasma
membrane followed by subsequent invagina-
tions from the endosomal membrane to create a
multivesicular body [16]. Upon fusion of the
outer membrane with the plasma membrane,
the intraluminal vesicles are released as exo-
somes into the extracellular space. This review
will be focused specifically on exosomes,
although it should be noted that most biological
samples such as blood contain a mixture of
ectosomes and exosomes, whichmay be difficult
to separate [17, 18]. However, there are many
similarities between these two particles, both
being fundamentally dependent on budding
from the plasmamembrane, and they may share
a number of biological functions [15].
Exosomes consist of a lipid bilayer and a
cytosol, within which is transported a ‘‘cargo’’ of
soluble molecules. Exosome membrane proteins
include those involved in membrane budding
and fusion (common to all exosomes, as well as
to lysosomes, which share a common endoso-
mal origin) as well as cell-specific receptors
believed to be involved in exosome targeting to
receiver cells [16]. The cargo includes proteins,
mRNA, and both large and small noncoding
RNA. Different mechanisms are used to load
protein and RNA cargoes. Protein loading
mechanisms are the better understood and
include the endosomal sorting complexes
required for transport proteins (ESCRT) and
tetraspanins [19]. RNA loading mechanisms are
less clear, but some studies have identified
sequence motifs enriched in exosomal miRs
that are required for their interaction with RNA
binding proteins [19, 20]. The exosome mem-
brane serves to protect the cargo from nucleases
present in the blood as well as from the immune
system, exosomes are thus able to deliver a
complex signal consisting of multiple proteins
and RNAs to the receiver cell, which they do
through an active uptake mechanism either by
fusing with the plasma membrane or by endo-
cytic internalization followed by fusion with
the endosome membrane. This can be visual-
ized with lipophilic dyes [21].
EXOSOMES AND CIRCULATING
MIR AS BIOMARKERS
FOR CARDIOVASCULAR DISEASE
Biomarkers are a useful diagnostic tool in many
areas of cardiovascular medicine. We will here
take acute myocardial infarction (AMI) as an
example. ST segment elevation myocardial
infarction (STEMI), the most severe form of the
disease in which a coronary artery is completely
blocked, is treated by reperfusion, and this is
most effective if performed soon after the
infarction [22, 23]. Any delay in the time to
reperfusion following a patient’s arrival at the
hospital is associated with a higher risk of
in-hospital mortality and current guidelines
recommend treatment within 90 min [22, 23].
It is therefore critical to rapidly confirm a
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suspected STEMI. This is currently performed by
analysis of cardiac troponin (TNNI3, TNNT2)
plasma protein levels. These proteins are highly
expressed in cardiomyocytes and are released
into circulation upon infarction-induced
necrosis [24]. However, troponin levels do not
begin to rise until 4–6 h after infarction [24] and
thus reperfusion must be initiated before these
results are obtained [22]. Furthermore, any
condition leading to such necrosis, such as
sepsis or cardiotoxicity following chemother-
apy, can give a false-positive result [24]. There is
therefore a need for a biomarker that is both
more specific for AMI and that can provide a
faster diagnosis.
Both earlier diagnosis and increased speci-
ficity could be achieved by using a ‘‘pre--
necrotic’’ biomarker, a signal actively released
by the injured heart before necrosis begins.
Hypoxia has been shown in vitro to induce
cardiomyocyte release of exosomes carrying a
protein cargo consisting of the cytokine TNFa
[25] and the heat shock protein HSP60 [26].
Therefore, it is not unreasonable to suggest that
in vivo a cardiomyocyte that is in a state of
hypoxia following AMI, but is not yet necrotic,
might release exosomal endocrine signals into
the blood. In support of this hypothesis, we
know that there is an increase in plasma exo-
somes in the 2 days following coronary artery
bypass surgery [7], indicating that injury to the
cardiovascular system leads to exosome release.
Since the discovery that micro RNA exists in
a stable form in the blood [27], much interest
has focused on the potential of so-called circu-
lating microRNA as a biomarker, and evidence is
accumulating that these may be useful in the
diagnosis of diseases such as cancer [27] as well
as cardiovascular disease [28, 29]. Stabilized miR
seems to be present in blood in two forms: it
may be protected from nucleases either by an
exosome-based mechanism or by extra-vesicular
complexing to proteins such as the silencing
effector protein AGO2 [30] or the RNA binding
protein Nucleophosmin-1 [31]. Some of this
protein-bound miR may be released upon
necrosis following AMI, although it should be
noted that there is evidence both for active
release of protein-complexed miR [31] and for
active sorting such that particular miRs are
bound to proteins while others are loaded into
vesicles [30]. In addition, AGO2 has been shown
to be present in exosomes [3], suggesting that
some protein-bound miR may be of exosomal
origin.
Most studies of AMI biomarkers have taken a
candidate gene approach, tending to focus on
miRs known to be highly expressed in the heart.
For example, the cardiomyocyte-specific
miR-208a [32, 33], which is expressed from an
intron within alpha myosin heavy chain [34],
and the more general muscle-expressed miRs
such as miR-1-1/miR1-2, miR-133a/b, and
miR-499 [32, 33, 35, 36] have been shown to
increase following AMI by a number of groups.
miR-1-2 and miR-133a are produced from the
same primary transcript—a long noncoding
RNA calledMIR133A1HG—and share a common
promoter [37] while miR-499 is expressed from
an intron within another myosin heavy chain
gene, MYH7B, expressed in cardiomyocytes as
well as in skeletal and smooth muscle [38]. One
problem with looking at miRs highly expressed
in the heart is that one might argue that their
presence in circulation results from passive
release following necrosis, and indeed some do
correlate with cardiac troponin [35, 39]. How-
ever, there is also evidence that some rise more
quickly [39]. An analysis of blood taken from
patients undergoing transcoronary ablation of
septal hypertrophy (TASH)—a surgical inter-
vention resembling AMI, in which overgrowth
of the ventricular septum is reduced by induc-
ing a controlled infarction of the affected area—
which allows blood sampling at early time-
points, found significant plasma increases in
miR-1 and miR-133a only 15 min after surgery
[33]. Thus, there is circumstantial evidence for a
pre-necrotic release mechanism.
In vitro data indicate that cells select specific
miRs for release while retaining others [40] and
that not all miRs found in exosomes are
expressed by the parent cell [1]. Injury induces
gene expression changes, for example hypoxia
induces expression of miR-210 in cardiomy-
ocytes [41]. Thus, it is perhaps not logical to
assume that miRs expressed by healthy car-
diomyocytes will be those released upon injury.
Indeed, unbiased biomarker screens utilizing
techniques such as microarray analysis have
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identified many unexpected changes. Within
the heart itself, one study found 47 changed
miRs 7 days post AMI [42]. Changes in circu-
lating micro RNA may be even higher: one
study found 121 significantly changed miRs
following AMI (of which 63% are downregu-
lated) [43], while another found 20 upregulated
and 14 downregulated miRs [35]. Many of these
dysregulated circulating miRs are not car-
diomyocyte-specific, but as the authors note
[43], there is no particular reason to assume that
changed miRs should be of cardiomyocyte ori-
gin, other cell types such as endothelium may
also contribute to the AMI response.
Despite these data showing that gene
expression changes upon injury, indirect evi-
dence does support the hypothesis that mus-
cle-type miRs highly expressed under normal
conditions may be released upon injury. Work
in a mouse model of AMI shows that miR-133a
is downregulated in cardiomyocytes within the
infarct region [44]. This coincides with the time
that, based on analysis of patient serum, we
assume that miR-133 exosomes are produced
and thus suggests that miR-133a present in
healthy cells may be targeted to exosomes upon
injury. Direct evidence for this is lacking at
present, but these results are intriguing, not
least because the same authors demonstrated
that miR133a-containing exosomes released by
H9c2 rat embryonic myoblasts are functional, as
shown by reduced expression of a luciferase
reporter when applied to HEK293 cells [44].
Exosomes carry a complex message consist-
ing of a mix of several molecules. Therefore, the
true value of exosomes as biomarkers may be to
define a molecular signature for AMI (Fig. 1). It
is likely that this will depend not on analysis of
one or two markers as in the studies above, but
on a more sophisticated analysis of combina-
tions of co-released miRs, and perhaps other
cargo such as proteins (exosomal clusterin is
increased in pericardial fluid following AMI
[45]) or lncRNA [46, 47]. Towards this goal, a
recent paper has proposed that a panel of dif-
ferentially expressed miRs can be used to dif-
ferentiate Takotsubo cardiomyopathy from AMI
[48]. Takotsubo cardiomyopathy has similar
symptoms to AMI but is caused by stress-in-
duced changes in ventricular function rather
than by coronary artery occlusion. The study
found that expression analysis of synchronised
changes in four circulating miRs could differ-
entiate the two conditions.
The use of circulating miRs as biomarkers is
gaining increasing interest within many areas of
cardiovascular medicine beyond AMI including
coronary artery disease, atrial fibrillation,
hypertrophic cardiomyopathy, and heart failure
[49–51]. For example, there is evidence that the
blood levels of miRs normally expressed in the
endothelium are decreased in patients with
coronary artery disease [52]. Valve disease is
another area in which circulating miR
biomarkers have been explored [53]. A circu-
lating miR signature for the congenital disease
bicuspid aortic valve (BAV) consisting of
miR-122, miR-130a, and miR-486 has been
proposed [54] and this seems to differ from the
profile of miR expression changes observed
within the valve tissue itself [55].
Although circulating miRs and exosomes in
general certainly show potential as a biomarker,
a number of technical challenges remain to be
overcome before they can be routinely utilized
in the clinic [56, 57]. Assaying miR by RT-qPCR
is a more complex and time-consuming proce-
dure than a simple ELISA assay and this may
negate some of the temporal advantage over the
troponin assay. In addition, low miR expression
levels make accurate quantification difficult,
endogenous controls are not standardized, and
a lack of reproducibility has also been noted in
many such studies.
EXOSOMES OFFER
AN ALTERNATIVE TO STEM CELL
THERAPY
Ischemia resulting from myocardial infarction
results in extensive cardiomyocyte necrosis,
formation of a fibrotic scar, and compensatory
ventricular remodeling, often leading to heart
failure at a later date [58]. Surgical intervention
such as coronary artery bypass graft can restore
blood flow and limit damage but cannot
regenerate tissue already lost. Stem cell therapy
offers hope in this regard [59, 60]. Stem cells
derived from a variety of sources including bone
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marrow hematopoietic (HSCs) [61] and mes-
enchymal (MSCs) [62] stem cells as well as
embryonic stem cells (ESCs) [63] have been
shown to differentiate into cardiomyocytes in
animal models or to improve outcomes in
clinical trials.
The adult heart has been shown to contain a
small population of endogenous stem cell-like
cells, marked by expression of c-kit [64] and
these also offer hope for regeneration. Resident
stem cells may be isolated and grown from
myocardial biopsies as a result of their capacity
to form multicellular clusters known as cardio-
spheres and these cardiosphere-derived cells
(CDCs) may be used for therapy [65]. Although
transplant of autologous CDCs derived from the
patient themselves would be ideal, and these
have been shown to reduce scarring and
improve cardiac function in a phase one clinical
trial [66], this procedure is limited by
time-consuming isolation and growth proto-
cols. Allogenic cell transplants, in which the
cells are not derived from the patient, offer a
more standardized, off-the-shelf solution.
Surprisingly, allogenic intramyocardial
injection of CDCs into the infarct periphery in
rats does not result in a large immune response
[67]. This seems to be because the cells them-
selves do not survive long in the host (less than
1% remain after 3 weeks) [67], and their main
function seems to be a paracrine one. Indeed,
pre-treatment of human CDCs with a drug to
inhibit exosome secretion eliminates their
beneficial effects when injected into mice fol-
lowing an induced MI [68]. In fact, evidence is
accumulating suggesting that survival of
engrafted stem cells is often poor [69] and that
the beneficial effects of many stem cell thera-
pies, including embryonic [70], induced
pluripotent [71], ESC-derived cardiac progeni-
tors [72, 73], and mesenchymal [74, 75] result
not because the injected stem cells differentiate
into new tissue but instead because they seem
to act as a paracrine source of exosomal growth
factors. For example, in a mouse model of AMI,
intramyocardial injection of exosomes derived
from ESCs increased the number of resident
progenitor cells as well as increasing capillary
density around the infarct, resulting in
improved cardiac function [70]. Exosomes
derived from cardiac progenitor cells isolated
from the atrial appendages of neonatal children
improved heart function in a rat AMI model
[76]. Similarly, MSC exosomes have been shown
to reduce infarct size in a mouse model [74]
while pre-treatment of CDCs with MSC-derived
exosomes improved survival and reduced
fibrosis in a rat AMI model [77]. Exosomes have
Fig. 1 Diagnostic exosome applications. aCurrent diagnosis
of acute myocardial infarction relies on detection of proteins
such as cardiac troponin, which are passively released into the
circulation upon cardiomyocyte necrosis. Necrosis may also
release protein-complexed miRNA into circulation. b Active
release of exosomes by injured cells offers the potential for a
faster andmore speciﬁc pre-necrotic diagnosis. Exosomesmay
be released within minutes of infarction and carry a complex
cargo, which may include miRNA, mRNA, lncRNA, and
proteins, offering potential for detection of a unique
infarction molecular ﬁngerprint
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been shown to exert their regenerative effects
via a number of mechanisms including stimu-
lating differentiation of endogenous resident
stem cell populations [70], by conferring a car-
dioprotective effect on existing cardiomyocytes
[78, 79] and by promoting angiogenesis [80].
Exosomes have also been shown to have a
beneficial effect in other cardiovascular settings.
For example, MSC exosomes have been shown
to reduce vascular remodeling in a mouse
model of pulmonary hypertension [81], exo-
somes derived from CD34? HSCs have been
shown to mediate the angiogenic properties of
these cells in subcutaneous or corneal mouse
implants [80], while endothelial progenitor cell
(EPC) exosomes mediate neovascularization in a
mouse model of hind limb ischemia [82].
In vitro studies have demonstrated that EPC
exosomes bind to and are taken up by
endothelial cells of the vasculature and are able
to transfer mRNA to these cells [83]. Cardiac
fibroblasts have been shown to produce exo-
somes, which transfer miRs to receiver cells, and
this is important in cardiac hypertrophy [5].
An interesting addition to these studies is the
finding that exosome-mediated communica-
tion from cardiac endothelial cells can improve
survival of engrafted cardiac progenitor cells
(CPCs). Co-injection of a DNA construct
encoding the hypoxic-induced transcription
factor HIF1 improved survival of CPCs in a
mouse AMI model [84]. This seems to be
because endogenous endothelial cells express-
ing HIF1 driven by the vector produce exosomes
with a higher concentration of the pro-survival
miRs miR-126 and miR-210, which are then
taken up by CPCs and induce a metabolic
switch in these cells [84].
The therapeutic potential of these observa-
tions are enormous. If, as seems to be the case,
exosome-mediated signals produced by stem
cells are more important to regeneration than
the cells themselves, it may be possible to iso-
late this factor to produce a ‘‘cell-free’’ form of
stem cell therapy (Fig. 2). This has the advan-
tage of convenience, offering the potential for
an ‘‘off-the-shelf’’ solution, and also the poten-
tial for bulk production in vitro. Finally, exo-
somes therapies may reduce the risks associated
with stem cell therapies.
ENGINEERING OF EXOSOMES
FOR SPECIFIC TARGETING
AND DRUG DELIVERY
Synthetic vesicles (liposomes) have been used as
an artificial drug delivery vehicle for over
40 years [85]. These vesicles consist of a simple
lipid bilayer, sometimes conjugated to mole-
cules such as polyethylene glycol to aide
immune evasion. Exosomes offer the potential
for a natural drug delivery system, and have a
number of advantages over liposomes. Exo-
somes, in contrast to liposomes, express a
complex array of proteins within the membrane
and these may be modified to display surface
markers. Exosome targeting to a specific recei-
ver cell or tissue is generally achieved by surface
display of a specific ligand. Use of a short pep-
tide is preferable to use of a whole protein
because this is less likely to stimulate an
immune response, and is easier to clone [86].
This is most easily achieved by transfecting cells
in vitro with an expression construct encoding
a fusion protein containing the ligand of inter-
est fused to an endogenous exosome membrane
protein [86, 87]. Examples of suitable exosome
proteins include MFGE8 and LAMP2B.
MFGE8 (Lactadherin) is a secreted glycopro-
tein first isolated from milk, but later shown to
be present in the exosomal membrane of den-
dritic cells [88]. It contains two motifs, an RGD
domain, which interacts with integrins, and a
C1C2 domain, which mediates its interaction
with membranes, including those of exosomes.
Of interest to cardiovascular medicine is the
observation that MFGE8 is expressed by blood
vessels and blocking antibodies raised against it
inhibited VEGF-mediated neovascularization in
a rodent limb ischemia model [89]. This is
thought to involve interaction of the RGD
domain with integrins [89], although the pos-
sibility that MFGE8 could be presented to target
cells on exosomes was not addressed. Expres-
sion of ectopic proteins fused to the MFGE8
C1C2 domain (without the integrin-interacting
RDG domain) allows targeting to the exosome
membrane [90], although it should be noted
that MFGE8 is not exclusively expressed in
exosomes but is also present in other species of
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extracellular vesicle [91]. Lysosome-associated
membrane proteins (LAMPs) are transmem-
brane glycoproteins that are specifically tar-
geted to the lysosome membrane by a motif at
the C-terminal [92]. Fusion of a peptide from a
rabies viral glycoprotein (which binds the
acetylcholine receptor) to LAMP2b successfully
targeted exosomes to the mouse brain [87, 93].
Exosomes may also be modified to carry an
exogenous cargo. Cargo-loading strategies can
be divided into those that employ direct load-
ing of isolated exosomes and those that take
advantage of endogenous cellular cargo loading
mechanisms [85, 94]. The former is often used
for RNA and siRNA loaded directly into purified
exosomes by electroporation is functional
[87, 93], despite the fact that this method seems
to precipitate RNA [95]. Isolated exosomes can
also be loaded with a number of lipophilic
molecules including anticancer drugs such as
doxorubicin [94]. Transfection of donor cells
with an expression plasmid can be sufficient to
generate RNA-containing exosomes and this
strategy has been used to produce miR-146b
exosomes [96]. This method has also been used
to generate exosomes carrying a cargo of syn-
thetic anti-miR [97] indicating an alternative
therapeutic strategy. An alternative approach is
to manipulate cell-sorting mechanisms by
expressing a fusion protein consisting of an
exosomal membrane protein (LAMP2B) linked
to an RNA-binding domain (bacteriophage
MS2) such that over-expression of an RNA car-
rying the motif recognized by MS2 results in
production of RNA-containing exosomes
[98]. This method is perhaps best suited to
mRNA rather than short RNAs. This article is
based on previously conducted studies and does
not involve any new studies of human or ani-
mal subjects performed by any of the authors.
Fig. 2 Therapeutic exosome applications. Exosomes have
shown much promise in the treatment of myocardial
infarction. a Much of the therapeutic beneﬁts of stem cells
appear to be mediated by paracrine exosome-based mech-
anisms, and thus extraction and delivery of such exosomes
offers a lot of potential for a form of cell-free stem cell
therapy, reducing the risks of stem cell injection and
allowing production of a standardized off-the-shelf prod-
uct. b Exosomes may be engineered for use as a natural
drug delivery vehicle. Exosomes released from cells grown
in vitro may be loaded with RNA by electroporation.
Lipophilic drugs such as doxorubicin may be directly
loaded into exosomes. c An alternative strategy is to
transfect cells with an expression plasmid encoding an
exosome-targeted protein, mRNA, or miRNA to take
advantage of the cell endogenous sorting mechanisms to
achieve exosomes-loading
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CONCLUSIONS
Exosomes show great potential to improve both
diagnosis and therapy within cardiovascular
medicine, but many questions remain and we
are some way away from bringing them into the
clinic.
Pre-clinical studies have demonstrated that
exosome-based signaling is both widespread and
important in the cardiovascular system and the
evidence suggests that exosomes are released
into circulation, yet we know very little of the
function of this novel form of endocrine signal-
ing.While exosome-based biomarkers offer great
potential in the development of unique signa-
tures for specific cardiovascular disease, a greater
understanding of the biological functions of
these particles is needed before we can draw firm
conclusions based on their blood levels. For
example, many studies of AMI biomarkers make
the assumption that the same miRs expressed in
healthy cardiomyocytes will be released upon
injury, but why should this be the case? Perhaps
novelmiR signaling pathways are activated upon
injury, and functional work on the many novel
miR biomarkers identified in microarray screens
[35, 43] should be a fruitful avenue for explo-
ration. Additionally, it is difficult at present to
distinguish exosomal miR from other forms of
circulating miR, as well as to distinguish exo-
somes from other classes of nanoparticles, and
methods to improve these distinctions are likely
to be valuable in the development of biomarkers.
Inconsistencies within the current data are
attributable in part to biased, non-random
selectionof potential biomarkers [51] aswell as to
technical challenges associated with these assays
[56, 57]. Of particular importance to their future
utility will be the development of more sensitive
assays for quantification of the low levels of miR
found in the blood.
Similarly, in therapeutics, exosomes offer
great potential as a result of their ability to evade
the immune system and to offer specific target-
ing. Yet our knowledge of exosome synthesis and
cargo-loading pathways are limited, and as our
knowledge of the basic science increases, this
should improve our ability to manipulate exo-
somes for therapeutic use. In particular, we do
not yet fully understand how RNA is sorted and
loaded into exosomes, while many proteins used
to target ligands to exosomemembranes are also
expressed in lysosome membranes, and thus are
not specific to exosomes.
Despite these challenges, the emerging field
of exosome signaling offers many opportunities
for cardiovascular medicine.
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